InvestorTalk Alert: Andre Larente from Diagnos Inc. to host on Thursday, September 5, 2024

written by Raj Shah | September 4, 2024
InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, September 5th, at 9 AM EST, featuring Andre Larente, President, CEO, and Director of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF). To participate in this engaging discussion, please click here

Currently, DIAGNOS holds $\underline{76,766,767}$ shares outstanding and has a market capitalization of $\underline{CAD\$30,322,873}$.


In preparation for tomorrow's InvestorTalk, here are the four most recent news releases from DIAGNOS for your review, which are listed below:

- August 22, 2024 DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders - <u>click here</u>
- August 20, 2024 DIAGNOS Successfully Completes ISO 13485
 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada click here
- June 05, 2024 DIAGNOS Announces Closing of Second and Final Tranche of Private Placement <u>click here</u>
- May 21, 2024 DIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreement - <u>click</u> here

5-Data Points from DIAGNOS' news release titled, DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada:

- 1. **ISO 13485** / **MDSAP Certification:** DIAGNOS has successfully completed its ISO 13485 audit and received certification, allowing the company to move forward with FDA and Health Canada.
- 2. Medical Device Single Audit Program (MDSAP): The certification is crucial for the commercialization of DIAGNOS' flagship product, CARA, which focuses on early detection of health issues through AI and retinal imaging.
- 3. **Global AI Healthcare Market Growth:** The global AI healthcare market is projected to grow from USD \$19.27 billion in 2023 to USD \$613.81 billion by 2034, with a CAGR of 36.83% between 2024-2034.
- 4. **Regulatory Approvals:** DIAGNOS is obtaining regulatory licenses in Canada (Health Canada) and the USA (FDA) for four new modules aimed at detecting retinal conditions, including Age-Related Macular Degeneration and Diabetic Retinopathy.
- 5. **Expanding Product Suite:** DIAGNOS has evolved from offering a single diabetic test to a broader suite of diagnostic tools, accelerating both profitability and patient satisfaction.

(09.04.2024 at 6:00 AM EST, <u>Source</u>)



For more information on Diagnos Inc., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.